Close



Feb 23, 2024 08:01AM
Feb 23, 2024 08:00AM
Feb 22, 2024 07:51AM
Dec 9, 2023 12:30PM
Aug 2, 2023 07:00AM
May 23, 2023 10:00AM
May 23, 2023 10:00AM NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
May 22, 2023 04:05PM
May 22, 2023 04:04PM
May 4, 2023 07:00AM
Mar 28, 2023 04:06PM
Mar 28, 2023 04:05PM
Feb 26, 2023 03:00PM
Feb 23, 2023 08:01AM Blueprint Medicines (BPMC) to Regain Global Rights to GAVRETO from Roche
Feb 23, 2023 08:00AM
Feb 16, 2023 07:00AM
Feb 10, 2023 08:00AM
Feb 10, 2023 08:00AM
Feb 3, 2023 09:00AM
Jan 23, 2023 08:01AM
Jan 23, 2023 08:00AM Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
Jan 5, 2023 08:06AM
Jan 5, 2023 08:00AM
Dec 11, 2022 05:30PM
Nov 22, 2022 04:37PM
Nov 22, 2022 04:36PM
Nov 1, 2022 08:00AM
Aug 17, 2022 07:08AM Blueprint Medicines (BPMC) Announces Positive Top-line Results from PIONEER Trial of AYVAKIT in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
Aug 17, 2022 07:00AM
Aug 2, 2022 07:00AM
Jun 30, 2022 07:16AM
Jun 30, 2022 07:15AM
Jun 9, 2022 07:07AM
Jun 9, 2022 07:00AM
May 3, 2022 07:00AM Blueprint Medicines Reports First Quarter 2022 Results
Mar 25, 2022 10:15AM
Feb 16, 2022 07:00AM
Jan 28, 2022 08:01AM
Jan 28, 2022 08:00AM
Jan 10, 2022 08:16AM
Jan 10, 2022 08:00AM
Dec 30, 2021 08:51AM Blueprint Medicines Completes Acquisition of Lengo Therapeutics
Dec 6, 2021 04:02PM
Dec 6, 2021 04:01PM
Nov 29, 2021 07:02AM
Nov 29, 2021 07:00AM
Jul 29, 2021 07:00AM
Jul 28, 2021 08:00AM
Jun 16, 2021 03:52PM Blueprint Medicines (BPMC) Confirms FDA Approves AYVAKIT for the Treatment of Adults with Advanced Systemic Mastocytosis
Jun 16, 2021 03:50PM

251,875 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All